Tetraphase hires Patheon to make its synthetic antibiotic eravacycline

By Gareth Macdonald

- Last updated on GMT

Source Google maps
Source Google maps
Tetraphase Pharmaceutical has hired Patheon UK Limited to make and test the synthetic antibiotic eravacycline.

The deal – details of which were set out in a US Securities and Exchange Commission (SEC) filing​ – will see Patheon turn the active pharmaceutical ingredient (API) into the dosage form at its facility in the UK.

The contractor – which is part of Netherlands-headquartered contractor Patheon NV - will also conduct quality control, quality assurance, analytical testing and stability testing and packaging.

Tetraphase also said it expects to sign two further agreements with Patheon covering the manufacture of eravacycline at its sites in Greenville, North Carolina and Ferentino, Italy.

More contracts 

The Massachusetts-based developer will manufacture the active pharmaceutical ingredient (API) and supply it to the three Patheon sites.

Tetraphase has “agreed to order from Patheon at least a certain percentage of its annual commercial requirements for eravacycline in the United States and European Union each year for the term of the Master Agreement​.”

The agreement ends in December 2022, however, it will renew automatically for four two year terms.

The manufacturing contract is the first made public by Patheon since Thermo Fisher Scientific announced its intention to acquire the contractor in May​. 

Synthetic antibiotic

Eravacycline, Tetraphase’s lead candidate, is designed to treat infections caused by multidrug-resistant (MDR) Gram-negative bacteria.

The US Food and Drug Administration (FDA) has assigned the drug Qualified Infectious Disease Product​ (QIDP) and Fast Track status. It is currently being examined in a Phase III​ trial.

Eravacycline, like others in Tetraphase's pipeline, was developed using synthesis know how detailed in a paper​ published by researchers at Harvard Univerity in 2005.

Related news

Show more

Related products

show more

Powered by Ingredients + Innovation

Powered by Ingredients + Innovation

Content provided by Univar Solutions USA | 07-Oct-2024 | Product Brochure

In partnership with our industry-leading supplier partners, Univar Solutions Pharmaceutical Ingredients is proud to introduce Powering Healthy Tomorrows.

Reliability, scale, and security of supply

Reliability, scale, and security of supply

Content provided by Univar Solutions USA | 28-Aug-2024 | Product Brochure

Univar Solutions Pharmaceutical Ingredients is proud to offer one of the most expansive portfolios of 15,000+ products, including high-purity solvents,...

Related suppliers

Follow us

Products

View more

Webinars